0
Business
Cancer Drug Developer Erasca Sinks by Record 55% After Patient Death
April 28, 2026
Scroll
Posted 2 hours ago by
Erasca Inc. shares plunged as much as 55 Tuesday after the cancer-drug developer said one patient withdrew from its clinical trial and later died after suffering severe side effects related to the treatment.
Bloomberg
Coverage and analysis from United States of America. All insights are generated by our AI narrative analysis engine.
United States of America
Bias: lean left
People's Voices (0)
Leave a comment
0/500
Note: Comments are moderated. Please keep it civil. Max 3 comments per day.